Xbrane Biopharma AB (publ) (OM: XBRANE)
Health Care · Biotechnology · SE
Skr11.40
-18.28% today · -24.0% 1Y
Xbrane Biopharma AB (publ) (OM: XBRANE) operates in the Biotechnology industry within the Health Care sector. The company is valued at $23.72M and employs 29 people.
Over the last twelve months the share price has lost 24.0%, trading between 5.42 and 29.00.
Tweenvest scores Xbrane Biopharma AB (publ) across four factors: quality 40/100, value 46/100. Its strongest factor is value.
XBRANE price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $23.72M
- Revenue (TTM)
- $8.59M
- P/E
- —
- EPS
- -3.95
- Dividend yield
- —
- Beta (5Y)
- 0.78
- 52-week high
- Skr29.00
- 52-week low
- Skr5.42
- Avg volume (3M)
- —
- Shares outstanding
- 20.61M
- Employees
- 29
- Next earnings
- —
About Xbrane Biopharma AB (publ)
Xbrane Biopharma AB (publ) is a biotechnology firm, founded in 2008 and based in Solna, Sweden, that specializes in the creation, manufacturing, and distribution of biosimilar medications. The company's development pipeline includes Xlucane, a ranibizumab biosimilar presently undergoing pivotal Phase III clinical trials. This therapeutic candidate is being evaluated for the treatment of several serious eye conditions, including wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion. In its earlier, preclinical stages, Xbrane is progressing a range of biosimilars: Xcimzane: Targeting autoimmune diseases such as rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, psoriasis, and Crohn's disease. Xoncane: Designed for acute lymphocytic leukemia. Spherotide: Intended for prostate cancer, breast cancer, endometriosis, and uterine myoma. Xdivane: Developed for various cancers, including melanoma, lung cancer, head and throat cancer, bladder cancer, urinary tract cancer, and renal cell carcinoma. Moreover, Xbrane has established a strategic partnership with STADA Arzneimittel AG. This collaboration aims to explore and potentially pursue joint development and commercialization opportunities for its preclinical biosimilar candidates, Xcimzane and Xdivane.
- ISIN
- SE0026598583
- Founded
- 2008
- Listed since
- Feb 3, 2016
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Polyrizon Ltd.NasdaqCM: PLRZ | $24.29M | $10.00 | +11.26% |
| Shuttle Pharmaceuticals Holdings, Inc.NasdaqCM: SHPH | $24.20M | $5.08 | -4.69% |
| Eutilex.Co.,LtdKOSDAQ: A263050 | $24.14M | ₩— | — |
| ABVC BioPharma, Inc.NasdaqCM: ABVC | $23.80M | $0.92 | -8.21% |
| GeneMatrix Inc.KOSDAQ: A109820 | $23.69M | ₩1,549.00 | -9.94% |
| Transgenic Group Inc.TSE: 2342 | $23.63M | ¥224.00 | -4.27% |
| Evaxion A/SNasdaqCM: EVAX | $23.60M | $2.83 | -7.82% |
| RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret A.S.IBSE: RTALB | $23.42M | TL2.32 | -10.77% |
Figures last refreshed Oct 18, 2026.